Age range: 50 - 75 years old, gender not restricted;
Patients diagnosed with Alzheimer's disease (AD) according to the AT(N) diagnostic framework (with positive amyloid protein PET test results);
MMSE score between 15 and 30 points, patients with mild to moderate Alzheimer's disease;
The patient has a fixed caregiver who is willing to accompany the patient throughout the corresponding program;
The patient has a literacy level above primary school, sufficient to complete the tests stipulated in the program;
The patient or the guardian consents to participate in this clinical trial voluntarily and signs the informed consent form.
You may not be if
Dementia caused by other diseases, such as vascular dementia, frontotemporal dementia, and Lewy body dementia, etc.;
The patient has other major systemic diseases, malignant tumors, chronic obstructive pulmonary disease or pulmonary fibrosis, etc. related to the lungs;
The patient's white blood cell and neutrophil levels are below the normal lower limit;
The patient has active infectious diseases, such as syphilis, AIDS, hepatitis B, hepatitis C;
The patient has a history of stroke, epilepsy, alcohol abuse, or abuse of psychotropic drugs;
Severe visual or hearing impairment, or those who cannot complete the relevant assessment due to other reasons;
Patients who have participated in other clinical trials within the last 2 months;
Other situations that the researchers consider not suitable for participating in clinical research.
